HONG KONG – Marking another step forward for South Korea's leading biosimilar developer, the Ministry of Food and Drug Safety (MFDS) approved domestic sales of Samsung Bioepis Co. Ltd.'s Renflexis (infliximab), a biosimilar of Johnson & Johnson's Remicade (infliximab). This is the second marketing approval for the company this year.